CONGRESS FOR VOTERS

Lisa Murkowski (R-AK)

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

S. 4472 · Senate bill Health

A Republican bill with 8 Democratic cosponsors · See all 15 cosponsors

Last activity — Held at the desk.

Passed one chamber, waiting for the other to take it up

Passed one chamber, and the other has not yet sent it to a committee or put it on its calendar.

The other chamber will hand it to a committee, place it on its calendar, or leave it where it is. Nothing has been decided, and a bill can sit here indefinitely.

Its path through Congress

  1. Introduced
  2. Passed Senate voice vote
  3. Awaiting House

The Senate by voice vote (members called out yes or no together): no senator's position on it was recorded.

What this bill would do

This Act, known as the ``Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026'', aims to extend the provisions of the Accelerating Access to Critical Therapies for ALS Act. It reauthorizes specific provisions through fiscal year 2031. The bill includes updates to the grant application process for expanded access grants. It also modifies requirements for FDA action plans regarding rare neurodegenerative diseases. Additionally, the bill introduces new reporting requirements for the Secretary of Health and Human Services.

Yes

  • Scored +5

    Does this make health care easier to get in general?

    The bill extends the timeframe for expanded access grants and research related to ALS treatments through 2031.

  • Scored +5

    Does this put more money into medical research?

    The bill reauthorizes grants specifically for ALS research through fiscal year 2031.

  • Scored +5

    Would people with disabilities be better off under this?

    The bill supports the development of therapies for ALS, a debilitating neurodegenerative disease.

The opposite

No question was scored the opposite.